Study Type
Interventional - Drug
The AXIOMATIC SSP study was a global, phase 2, randomized, double-blind, placebo-controlled, dose-ranging study of BMS-987177, an oral factor XIa inhibitor, for the prevention of new ischemic stroke or new silent brain infraction in patients receiving aspirin and clopidogrel following acute non-hemorrhagic stroke or transient ischemia attack (TIA).
The purpose of this clinical study was to determine whether the addition of an oral Factor XIa Inhibitor to aspirin and clopidogrel is more effective than standard therapy in secondary stroke prevention.
AXIOMATIC-SSP - ESC 2022 (download PDF)Interventional - Drug
Double-blind placebo-controlled dose-ranging RCT
27
367
2366
2019 - 2022
Bristol Myers Squibb
Back To Top